Oral Pleuromutilins BC-3205 & BC-3781
The pleuromutilins BC-3205 & BC-3781 belong to the first generation of pleuromutilins combining excellent oral bioavailability with great activity against gram-positive and gram-negative pathogens as well as atypicals.
In particular, both drug candidates are highly active against multi-drug resistant (MDR) pathogens including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia (i.e. macrolide and quinolone resistance), and vancomycin resistant Enterococcus faecium. They are characterized by excellent in vivo activities (e.g. pneumonia model), outstanding PK/PD parameters, allowing once a day dosing, and a novel mode of action.
Topical Pleuromutilin BC-7013
Nabriva owns a comprehensive topical program with the pleuromutilin BC-7013 being the most advanced drug candidate. BC-7013 belongs to a subclass of pleuromutilins which are characterized by outstanding activities against resistant gram-positive pathogens, in particular MRSA, and perfect PK/PD parameters in skin. Its properties qualify BC-7013 for the topical treatment of a number of bacterial associated or derived dermatological diseases.